Jackson Creek Investment Advisors LLC Takes $1.03 Million Position in Soleno Therapeutics, Inc. $SLNO

Jackson Creek Investment Advisors LLC bought a new stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) during the 3rd quarter, HoldingsChannel reports. The institutional investor bought 15,200 shares of the company’s stock, valued at approximately $1,028,000.

Other hedge funds have also added to or reduced their stakes in the company. Westfield Capital Management Co. LP boosted its holdings in shares of Soleno Therapeutics by 18.0% during the 2nd quarter. Westfield Capital Management Co. LP now owns 1,429,756 shares of the company’s stock worth $119,785,000 after buying an additional 218,511 shares in the last quarter. State Street Corp boosted its stake in Soleno Therapeutics by 20.2% during the second quarter. State Street Corp now owns 1,404,983 shares of the company’s stock worth $117,709,000 after acquiring an additional 235,784 shares in the last quarter. Geode Capital Management LLC boosted its stake in Soleno Therapeutics by 46.6% during the second quarter. Geode Capital Management LLC now owns 902,396 shares of the company’s stock worth $75,611,000 after acquiring an additional 286,660 shares in the last quarter. Emerald Advisers LLC grew its holdings in Soleno Therapeutics by 19.2% in the second quarter. Emerald Advisers LLC now owns 672,908 shares of the company’s stock worth $56,376,000 after purchasing an additional 108,427 shares during the period. Finally, Invesco Ltd. increased its stake in Soleno Therapeutics by 38.3% in the second quarter. Invesco Ltd. now owns 645,974 shares of the company’s stock valued at $54,120,000 after purchasing an additional 178,781 shares in the last quarter. 97.42% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on SLNO. Weiss Ratings restated a “sell (d-)” rating on shares of Soleno Therapeutics in a research note on Thursday, January 22nd. The Goldman Sachs Group set a $125.00 price target on Soleno Therapeutics and gave the stock a “buy” rating in a report on Tuesday, October 7th. Wolfe Research set a $60.00 price objective on Soleno Therapeutics in a report on Monday, January 12th. Wells Fargo & Company reiterated an “overweight” rating and issued a $114.00 target price (up from $106.00) on shares of Soleno Therapeutics in a report on Tuesday, January 20th. Finally, Robert W. Baird set a $107.00 price target on shares of Soleno Therapeutics in a research report on Tuesday, January 13th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $110.62.

Soleno Therapeutics Stock Performance

Shares of Soleno Therapeutics stock opened at $42.32 on Tuesday. Soleno Therapeutics, Inc. has a 52 week low of $37.95 and a 52 week high of $90.32. The company has a quick ratio of 15.88, a current ratio of 16.08 and a debt-to-equity ratio of 0.10. The business has a 50 day moving average price of $46.51 and a 200-day moving average price of $59.13. The company has a market cap of $2.27 billion, a PE ratio of -23.00 and a beta of -3.16.

Soleno Therapeutics (NASDAQ:SLNO) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.39. The company had revenue of $66.02 million for the quarter, compared to the consensus estimate of $47.46 million. Equities analysts anticipate that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current fiscal year.

Soleno Therapeutics Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.